- Home
- / Bavarian Nordic
Bavarian Nordic
Stock Price
KR218.3
2024-10-29
Market Capitalization
KR17.1 B
2024-10-29
Revenue
KR6.2 B
FY, 2025
Bavarian Nordic Summary
Company Summary
- Overview
- Bavarian Nordic is a pharmaceutical company that specializes in the research and development, manufacturing, and commercialization of vaccines. It provides mpox and smallpox vaccines as well as travel vaccines.
- Type
- Public
- Status
- Active
- Founded
- 1994
- HQ
- Planegg, DE | view all locations
- Cybersecurity rating
Table of Contents
Key People
Paul Chaplin, President & CEO
Anu Helena Kerns, Executive Vice President, Chief People Officer
Jean-Christophe May, Executive Vice President, Chief Commercial Officer
LocationsView all
6 locations detected
Planegg, Bayern HQ
Germany
13 Fraunhoferstraße
Morrisville, NC
United States
3025 Carrington Mill Blvd
Hellerup
Denmark
Philip Heymans Alle 3
Hørsholm
Denmark
Agern Alle 1
Kvistgård
Denmark
Hejreskovvej 10A
Zug, ZG
Switzerland
Grafenauweg 8
Bavarian Nordic Financials
Summary Financials
- Revenue (Q1, 2026)
- kr1.1B
- Gross profit (Q1, 2026)
- kr646.7M
- Net income (Q1, 2026)
- kr17.0M
- Cash (Q1, 2026)
- kr692.8M
- EBIT (Q1, 2026)
- (kr7.0M)
- Enterprise value
- $16.6B